Markus Dahlem

CEO, Newsenselab

Dr. Dahlem studied physics and mathematical biology in Aachen, Göttingen and Salt Lake City. In his academic carrier, he specialized in the emergence of biological rhythms in connection with diseases. Research stays took him to the Mathematical Biosciences Institute (USA) and the MPI for Physics of Complex Systems, among others. In 2016, he founded Newsenselab, a company that launched the first DTx for migraine. Newsenselab therapeutic focus ares are chronic episodic diseases and specializes in digital biomarkers to predict disease progression.

Social Media